8. Mesenteric Ischemia

Quick Recap

GI & Hepatology System, Protocol 8/13.

1. Definition & Classification

Acute mesenteric ischemia (AMI) = sudden compromise of intestinal blood flow, a true abdominal vascular emergency with historically high mortality (20-50%+) driven largely by DIAGNOSTIC DELAY — "pain out of proportion to exam" is the classic teaching precisely because early physical findings are often unimpressive relative to the severity of the underlying process.

Four mechanisms:

• Acute mesenteric arterial EMBOLISM (~40-50% of cases): embolus (typically cardiac source — AFib, post-MI mural thrombus, endocarditis) lodges in the SMA, classically just distal to the origin of the middle colic artery given the SMA's oblique takeoff angle — abrupt onset, often WITHOUT prior chronic mesenteric ischemia symptoms (no antecedent "intestinal angina")
• Acute mesenteric arterial THROMBOSIS (~25-30%): thrombosis of an already atherosclerotic, stenotic SMA (or celiac/IMA) origin — often has a preceding history of chronic mesenteric ischemia (postprandial pain, "food fear," weight loss) before the acute occlusive event
• Mesenteric VENOUS thrombosis (~10%): portal/superior mesenteric/splenic vein thrombosis, associated with hypercoagulable states (inherited thrombophilia, malignancy, cirrhosis/portal hypertension, recent abdominal surgery/inflammation, oral contraceptives) — typically a more INDOLENT onset (days) than arterial causes
• Non-occlusive mesenteric ischemia (NOMI, ~20-30%): splanchnic vasoconstriction/hypoperfusion WITHOUT a fixed occlusive lesion, occurring in the setting of low-flow states — cardiogenic/hypovolemic/septic shock, high-dose vasopressor use (especially vasopressin and high-dose norepinephrine), cardiopulmonary bypass, cocaine use — a critical diagnosis to consider in ANY critically ill patient with new abdominal symptoms/lactate rise on vasopressors, since the mechanism is physiologic rather than a discrete lesion to find on angiography

2. Pathophysiology

Interrupted arterial inflow or venous outflow -> mucosal ischemia first (most metabolically active/vulnerable layer) -> progressive transmural injury as ischemia persists -> bacterial translocation, bowel wall necrosis, perforation, peritonitis, and septic shock if unrecognized. The mucosa can suffer irreversible injury within hours while the bowel still appears grossly viable on initial inspection — this lag between mucosal injury and visible transmural/serosal change is central to why early recognition (before exam findings catch up to the underlying pathology) is the entire game in this disease.

3. Immediate Stabilization (ABCDE)

Airway/Breathing: support per standard indications if the patient progresses to septic shock/respiratory failure from bowel necrosis.

Circulation:

• Aggressive fluid resuscitation to optimize splanchnic perfusion, but recognize the tension with NOMI physiology — if the patient is already on vasopressors for shock, NOMI itself may be worsened by high-dose vasoconstrictor use, creating a genuine clinical dilemma between treating the systemic shock and protecting mesenteric perfusion
• Minimize/avoid vasopressin and high-dose alpha-agonist vasopressors where possible once NOMI is suspected or confirmed — these directly worsen splanchnic vasoconstriction; if vasopressor support is unavoidable, some centers use intra-arterial papaverine (a direct vasodilator) infused into the SMA via angiography catheter specifically to counteract the systemic vasoconstrictor's mesenteric effect while still treating the underlying shock
• Broad-spectrum antibiotics empirically once AMI is suspected, covering gram-negative and anaerobic gut flora, given the high likelihood of bacterial translocation/impending perforation
• Anticoagulation (heparin) for embolic/thrombotic arterial and venous causes once the diagnosis is confirmed or strongly suspected, balanced against bleeding risk if surgery is imminently planned — coordinate timing with the surgical/interventional team rather than reflexively anticoagulating before a procedural plan is set

Checklist:

4. Focused History & Examination

Classic triad for arterial embolic AMI: acute severe abdominal pain (often periumbilical, poorly localized) + pain OUT OF PROPORTION to a relatively benign/unremarkable abdominal exam + a source for embolism (AFib, recent MI, known cardiac thrombus, endocarditis). This disproportion between severe pain and unimpressive exam is THE classic diagnostic clue — a soft, minimally tender abdomen in a patient in agony should raise, not lower, suspicion.

Chronic mesenteric ischemia history (postprandial pain, food avoidance, weight loss) suggests a thrombotic-on-atherosclerotic mechanism rather than embolic.

Bloody diarrhea, hematochezia, or hematemesis are LATE findings suggesting mucosal sloughing/established infarction — their presence indicates the disease has already progressed significantly, not an early sign.

Peritoneal signs (rebound, guarding, rigidity) indicate transmural infarction/perforation and mandate emergent surgical exploration regardless of imaging timing — do not wait for CT confirmation in a patient with a surgical abdomen.

Risk factor review: AFib/cardiac thrombus source (embolic), atherosclerotic disease elsewhere/chronic mesenteric ischemia symptoms (thrombotic), hypercoagulable state/malignancy/cirrhosis/recent abdominal inflammation (venous), shock state/high-dose vasopressors/cardiopulmonary bypass/cocaine (NOMI).

5. Investigations

Lactate: elevated lactate supports the diagnosis but is a LATE and NONSPECIFIC marker — a NORMAL lactate does NOT exclude early AMI, since lactate rises only once significant tissue injury/anaerobic metabolism is established; do not use a normal lactate to reassure against the diagnosis in a patient with a compelling clinical picture.

Other labs: leukocytosis (nonspecific), metabolic acidosis, amylase/lipase mild elevation (nonspecific, can mimic pancreatitis), D-dimer (nonspecific but often elevated, more useful for excluding venous thrombosis with a very low value than for ruling in disease).

CT angiography (CTA) is the imaging modality of choice — rapid, widely available, evaluates both the mesenteric vasculature directly (embolus/thrombus location, venous thrombosis) AND bowel wall changes (thickening, decreased/absent enhancement, pneumatosis intestinalis, portal venous gas, mesenteric fat stranding, free fluid). Pneumatosis intestinalis or portal venous gas are highly concerning for transmural bowel necrosis and should prompt emergent surgical consultation regardless of hemodynamic status.

Conventional catheter angiography: historically the gold standard, now largely reserved for cases proceeding directly to endovascular intervention (thrombolysis, angioplasty, intra-arterial vasodilator infusion for NOMI) rather than as a primary diagnostic step, given CTA's speed and non-invasiveness.

Do not delay surgical consultation or CTA acquisition for serial exams in a patient with a compelling history — the diagnostic delay that historically drove AMI's high mortality was largely a failure to image early enough, not a failure of any single test's accuracy once ordered.

6. Evidence-Based Management

Emergent surgical and/or interventional radiology consultation as soon as AMI is suspected — in parallel with, not sequential to, diagnostic workup.

Embolic arterial AMI:

• Surgical embolectomy (open or increasingly via endovascular/hybrid techniques) remains first-line for a confirmed proximal SMA embolus, particularly with any peritoneal signs (need for concurrent bowel viability assessment/resection)
• Catheter-directed thrombolysis or mechanical thrombectomy is an option in carefully selected patients WITHOUT peritoneal signs (no need for immediate laparotomy), allowing a less invasive first attempt

Thrombotic arterial AMI (atherosclerotic origin):

• Endovascular revascularization (angioplasty/stenting) of the diseased origin is increasingly favored as first-line where anatomically feasible, given the underlying chronic atherosclerotic disease is often amenable to this approach
• Open surgical bypass (aortomesenteric or other bypass) reserved for endovascular failure or unsuitable anatomy, or when laparotomy is already required for bowel assessment/resection

Venous mesenteric thrombosis:

• Anticoagulation (heparin, then transition to long-term anticoagulation) is the primary therapy for most cases WITHOUT peritoneal signs/bowel infarction — venous AMI has a more favorable natural history than arterial disease and often responds to anticoagulation alone
• Catheter-directed thrombolysis considered for extensive/progressive venous thrombosis despite anticoagulation
• Surgery reserved for peritoneal signs/confirmed infarction
• Underlying hypercoagulable state workup once acute management is underway (malignancy screen, thrombophilia panel, liver disease evaluation)

Non-occlusive mesenteric ischemia (NOMI):

• Treat the underlying shock state aggressively (the root cause) while minimizing splanchnic-vasoconstricting vasopressors where the overall hemodynamic picture allows (Section 3)
• Intra-arterial papaverine infusion via angiography catheter is a specific NOMI-directed therapy, used to directly vasodilate the mesenteric circulation while systemic vasopressor support continues for the underlying shock
• Surgery reserved for peritoneal signs/confirmed infarction, as with the other subtypes

All subtypes — exploratory laparotomy indicated for: peritoneal signs, hemodynamic instability not explained by another cause, CT evidence of transmural necrosis/perforation (pneumatosis, portal venous gas, free air), or clinical deterioration despite revascularization attempts. "Second-look" laparotomy (planned re-exploration 24-48h after initial surgery) is a well-established damage-control strategy when bowel viability was equivocal at the index operation — allows deferred, more confident resection decisions once ischemic tissue has had time to declare itself, rather than over- or under-resecting under uncertainty at the first operation.

7. Organ Support

Aggressive fluid resuscitation balanced against NOMI physiology (Section 3); broad-spectrum antibiotics; vasopressor selection informed by mesenteric perfusion concerns where feasible; standard ICU supportive care for septic shock/multiorgan dysfunction if bowel necrosis has occurred; nutrition planning (often prolonged NPO/parenteral nutrition given extensive resection risk) once the acute surgical phase is managed.

8. Consultation Matrix

9. Monitoring Framework

Serial abdominal exam (frequent, given the evolving nature of ischemic injury), serial lactate trend (understanding its lagging nature), hemodynamic monitoring, post-revascularization monitoring for reperfusion injury/compartment syndrome, watch for delayed perforation signs even after apparently successful revascularization.

10. Complications

Bowel necrosis/perforation, septic shock, short bowel syndrome (extensive resection), reperfusion injury post-revascularization, abdominal compartment syndrome (see dedicated protocol), recurrent thrombosis/embolism, multiorgan failure. Prevention: early recognition despite unimpressive exam findings, prompt imaging and parallel surgical/IR consultation, appropriate anticoagulation for embolic/thrombotic/venous causes, vasopressor selection awareness in NOMI. Rescue: emergent laparotomy with resection, second-look laparotomy strategy, endovascular rescue techniques.

11. Escalation & De-escalation

Escalate: peritoneal signs at any point, hemodynamic instability, CT evidence of transmural necrosis/perforation -> emergent laparotomy.

De-escalate: successful revascularization (surgical/endovascular) or anticoagulation response (venous), resolving abdominal exam, stable/improving lactate and hemodynamics -> transition to standard postoperative or medical (anticoagulation) management, plan bowel function/nutrition recovery.

12. ICU Discharge Criteria

Hemodynamically stable, no evidence of ongoing bowel ischemia/necrosis, surgical source control achieved if needed (including confirmed viability at any second-look procedure), anticoagulation plan established for embolic/thrombotic/venous causes, nutrition plan in place (parenteral if extensive resection), underlying cause (embolic source, atherosclerotic disease, hypercoagulable state) addressed or being worked up.

13. Documentation & Medicolegal Checklist

14. Key Guidelines / Reference Reviews

Bjorck M, Koelemay M, Acosta S, et al. Editor's Choice – Management of the Diseases of Mesenteric Arteries and Veins: Clinical Practice Guidelines of the European Society for Vascular Surgery. Eur J Vasc Endovasc Surg. 2017;53(4):460-510 — primary contemporary reference for classification and management approach reflected in this protocol.

15. Controversies

Optimal first-line revascularization strategy (endovascular vs open surgical) for both embolic and thrombotic arterial AMI continues to evolve as endovascular techniques and institutional expertise mature, without a single universally preferred approach across all anatomic presentations. The precise vasopressor strategy in a patient with concurrent septic/cardiogenic shock AND suspected NOMI represents a genuine, unresolved clinical tension between treating the systemic circulation and protecting splanchnic perfusion — practice is individualized rather than protocolized. Timing and threshold for planned second-look laparotomy (fixed 24-48h interval vs symptom/marker-driven) varies by institutional practice.

16. References

1. Bjorck M, Koelemay M, Acosta S, et al. Management of the diseases of mesenteric arteries and veins: ESVS clinical practice guidelines. Eur J Vasc Endovasc Surg. 2017;53(4):460-510.
2. Acute Abdomen in the ICU chapter (imaging approach, pneumatosis/portal venous gas significance). Washington Manual of Critical Care, 4th ed, 2025 (Ch. 91 region).
3. Clair DG, Beach JM. Mesenteric ischemia. N Engl J Med. 2016;374(10):959-968.
4. Kaminsky O, Vitin A. Non-occlusive mesenteric ischemia: pathophysiology and clinical management. Ann Transl Med. 2019 (general reference for NOMI/vasopressor interaction).